SCHOTT Pharma invests in a new production facility in Serbia
Amid growing market demand, SCHOTT Pharma continues expanding its global manufacturing network and has decided to invest a double-digit million euro amount in a new production site for pharma drug containment solutions and delivery systems in Jagodina in central Serbia.
– With this move, we are strengthening our presence in Europe, improving our competitiveness, and increasing our manufacturing flexibility to meet the needs of our customers in the region – explains Andreas Reisse, CEO of SCHOTT Pharma. The ramp-up for the manufacturing of ampoules for the pharmaceutical industry is expected to start in the course of 2024.
As a pioneer in pharma drug containment solutions and delivery systems, the company supplies the global pharma industry with high-quality solutions to safely store and administer medications. As such, the site in central Serbia, is intended to produce ampoules that are suitable for storing injectable drugs, e.g., painkillers, inflammation inhibitors, and anesthetics. Other product groups might follow based on market demand.
The production site in Jagodina, a town of 35,000 inhabitants and the administrative center of the Pomoravlje County, is well on schedule: the groundbreaking ceremony will take place at the end of December. In the first phase, SCHOTT Pharma will create 130 new jobs, and 350 are planned for the expansion phase.
About SCHOTT Pharma
SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world – because human health matters. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 65 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia.
With over 1,000 patents and technologies developed in-house, a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA, headquartered in Mainz, Germany, is part of SCHOTT AG that is fully owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenues of EUR 821m in the fiscal year 2022.
Source/photo: schott-pharma.com
